Mutational spectrum
Missense mutations, nonsense mutations, splice site mutations, insertions, deletions, and genomic rearrangements.
Presently, more than 400 mutations are known for all 14 genes together. The majority of them (about 240) have been identified in the COL3A1 gene.
Analytical methods
Genomic sequencing of coding regions, eventually MLPA (multiple ligation dependent analysis) or array CGH for detection of genomic rearrangements and large deletions.
Analytical validation
Direct sequencing of both DNA strands; verification of sequence, MLPA and array CGH results with a second DNA extraction and a second PCR or hybridisation, respectively.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) The prevalence is estimated between 1:5000 and 1:100 000 depending on the EDS type. 1, 2 The autosomal recessively inherited EDS types are much rarer compared to the dominantly inherited EDS types.
1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable for most EDS types except for EDS type VIA, which is most prevalent in the Middle East.
Diagnostic setting
Yes No
Prenatal diagnosis is rarely requested for EDS. 
TEST CHARACTERISTICS
Negative predictive value:
Analytical sensitivity (proportion of positive tests if the genotype is present)
The analytical sensitivity should be nearly 100%, if a deletion/duplication diagnostic test has been made for genes with the possibility of a genomic rearrangement. However, regulatory mutations in non-coding regions are supposed to be missed with exon scanning techniques, even if these types of mutations have not yet been reported in EDS.
Analytical specificity (proportion of negative tests if the genotype is not present)
Analytical specificity is nearly 100% because false positives may at the most arise due to misinterpretation of rare polymorphic variants.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if only a quantification can be made case by case. Clinical sensitivity is highly dependent on the EDS type based on fulfilment of the clinical criteria as well as of the biochemical and ultrastructural dermal findings documented in the Villefranche nosology: 1, 2 It is 50-90% for EDS type I/II (COL5A1 and COL5A2 gene), 3, 4 which is genetically heterogeneous with additional, still unknown gene loci. It is 95% for EDS type IV (COL3A1 gene), 6 EDS types VIIA and VIIB (COL1A1 and COL1A gene, respectively) and EDS type VIA (PLOD1 gene). 7 Sensitivity is not known in the recessively inherited clinical entities including Brittle Cornea syndrome 1 and 2 (ZNF469 and PRDM5 gene), 11 D4ST1-deficient EDS (CHST14 gene), 8 FKBP14-deficient EDS, 12 dermatosparactic type (ADAMTS2 gene), 9 EDS progeroid form (B4GALT7 gene) and EDS spondylocheiro dysplastic form (SLC39A13 gene). 10 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if only a quantification can be made case by case.
Clinical specificity is nearly 100%.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
As all EDS types are fully penetrant, the positive clinical predictive value is 100%. However, depending on EDS type, there may be highly variable clinical expressivity.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: Nearly 100%. Index case in that family had not been tested: Five to ninty-five percent, corresponding to the detection rate in the genes of the different EDS types. This question arises quite often in EDS type IV if the index patient has died already. 
Describe the burden of alternative diagnostic methods to the patient
Initial clinical, biochemical, and ultrastructural investigations complement the molecular genetic analysis which, however, cannot replace the former. As ultrastructural analysis and collagen electrophoresis require a preceding skin biopsy, refusal of the patient towards this more invasive intervention compared with drawing a blood sample has to be respected.
3.1.3
How is the cost effectiveness of alternative diagnostic methods to be judged? Unknown.
Will disease management be influenced by the result of a genetic test?
No & Yes 2
Therapy (please describe)
As a causal therapy is not possible, all efforts centre on management.
Treatment with the b-blocker Celiprolol was shown in a randomized study to be associated with a decrease in arterial rupture in vascular EDS patients and might be the treatment of choice for physicians aiming to prevent major complications in patients with vascular EDS. 13 After surgical interventions, wounds should be closed without tension, preferably in two layers; deep stitches should be applied generously and cutaneous sutures left in place for twice as long as usual.
Regular follow-up/ control of the aorta and the large arteries regarding dilatation, aneurysm formation, or dissection by ultrasound or MRI -the regular intervals depend on the dynamic of the vascular changes.
Pregnancy is dangerous for the patient with EDS type IV and for her child because of tissue fragility leading to rupture of the uterus or the arteries before delivery -rupture of the arteries might occur also days post partum; hence, delivery has to be planned in advance and has to occur in a centre; C-section seems not to be a method to decrease such complications.
Ophthalmologic evaluation in EDS type VI and Brittle cornea syndrome.
Early orthopaedic and surgical measures in EDS types VIIA/B.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
Yes. If the test result is positive (please describe)
Frequent interdisciplinary follow-up, depending on EDS type (see above).
Specific therapeutic support of joints and musculature. Sport: avoid competitive and contact sport activities in EDS types with predominant involvement of joints. Protection of legs, arms, and face with athletes' pads or bandages against traumatic skin injuries leading to ugly scars. Scrutiny for eventually developing aneurysms, special caution during surgery, tight follow-up of pregnancy. Emergency health card noting information about the diagnosis, possible complications, and therapeutic measures; especially in EDS types with vascular involvement. Wound protection in EDS types with involvement of skin and a tendency to haematomas. When skin tears do occur, irregularly frayed wound margins should be excised and precisely adapted to allow (rapid) healing without dystrophic scarring, which is especially important in the case of facial wounds; numerous fine, atraumatic stitches should be used and left in place for twice as long as usual.
If the test result is negative (please describe) Follow-up is required in a clinically affected person, if the disease causing mutation could not be identified. In contrast, follow-up is dispensable in a family member, if a familial mutation has been excluded. 
Which options in view of

IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
In many cases, the genetic diagnostics contribute substantially to the classification of EDS type, if clinical, biochemical, and ultrastructural findings are not fully informative. Recognising clinical symptoms as belonging to the EDS and classifying them as a given EDS type is prerequisite for clinical prognosis, specific therapy, and official acceptance as severe handicap. Genetic testing gives insight to inheritance pattern and allows reasonable genetic counselling. In children with a tendency to haematomas, a suspicion of child abuse may be alleviated through the correct diagnosis of EDS type. The correct diagnosis will end a diagnostic odyssey and the unwarranted suspicion of hypochondria, and the appropriate patient organisation can now be approached.
